Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astria Therapeutics, Inc. - Common Stock
(NQ:
ATXS
)
5.360
+0.200 (+3.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astria Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
January 30, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
January 25, 2024
Via
Benzinga
$5.6M Bet On This Real Estate Stock? Check Out These 3 Stocks Insiders Are Buying
December 26, 2023
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.
Via
Benzinga
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Earnings Preview For Astria Therapeutics
November 10, 2023
Via
Benzinga
Expert Ratings for Astria Therapeutics
October 13, 2023
Via
Benzinga
Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
November 27, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
November 13, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For November 13, 2023
November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
Via
Benzinga
Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
November 10, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
November 09, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting
November 03, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th
October 30, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
HC Wainwright & Co. Maintains Buy Rating for Astria Therapeutics: Here's What You Need To Know
October 12, 2023
Via
Benzinga
Exxon Mobil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Thursday
October 12, 2023
Cantor Fitzgerald cut Hyliion Holdings Corp. (NYSE: HYLN) price target from $2 to $1. Cantor Fitzgerald analyst Andres Sheppard downgraded the stock from Neutral to Underweight. Hyliion shares fell...
Via
Benzinga
Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
October 11, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 11, 2023
Via
Benzinga
Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio
October 11, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Participate in Upcoming Investor Conferences
September 06, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics
August 31, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference
August 25, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
August 07, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema
July 20, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Names John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations
July 17, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit
July 14, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.